Quantinno Capital Management’s Keros Therapeutics KROS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.06M Buy
93,242
+66,271
+246% +$725K ﹤0.01% 2756
2026
Q2
$289K Buy
26,971
+3,212
+14% +$35.8K ﹤0.01% 3218
2026
Q1
$262K Buy
23,759
+2,639
+12% +$40.8K ﹤0.01% 3103
2025
Q4
$430K Sell
21,120
-11
-0.1% -$193 ﹤0.01% 2567
2025
Q3
$334K Buy
+21,131
New +$312K ﹤0.01% 2370

Other funds holding KROS

Quantinno Capital Management's KROS Position: Q3 2026 in Review

Quantinno Capital Management increased its Keros Therapeutics (KROS) stake by 246% in Q3 2026, buying an estimated $725K and bringing the position to 93,242 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2756.

Quantinno Capital Management first reported a position in KROS in Q3 2025 and has held it in 5 quarters since. 134 funds tracked by Wall St. Rank hold KROS as of Q3 2026.

  • Quantinno Capital Management held 93,242 shares of Keros Therapeutics worth $1.06M as of Q3 2026.
  • Quantinno Capital Management bought 66,271 Keros Therapeutics shares in Q3 2026, an estimated $725K.
  • Keros Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q3 2026, its #2756 holding.
  • Quantinno Capital Management first reported a position in Keros Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 134 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.

Based on Quantinno Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.